ArticleCNS neuroscience & therapeutics2026
Ferroptosis-Driven Neuronal Damage Exacerbation in Diabetic Stroke: Implications of SLC7A11 Inhibition.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDiabetes mellitus is a known contributor to worsened neurological outcomes following ischemic stroke, yet the underlying mechanisms remain elusive. Emerging evidence links ferroptosis to the extent of neuronal damage postischemic stroke. However, the role of ferroptosis in the context of diabetic stroke remains uncharted. SLC7A11, a key player in cellular antioxidant defense and ferroptosis regulation, has unexplored functions in diabetic cerebral ischemia/reperfusion.
methodsIn this study, we employed leptin receptor deficient (db/db) mice and wild-type (WT) littermates to model cerebral ischemic stroke. We harnessed quantitative proteomics to identify differentially expressed proteins and uncover potential signaling pathways. Infarct volume was assessed via 2,3,5-triphenyltetrazolium chloride staining. Neurobehavioral tests, immunohistochemistry, and immunofluorescence staining were employed to evaluate neuronal injury. The expression of SLC7A11 was assessed using Western blot and immunofluorescence staining. Dihydroethidium staining, flow cytometry, immunofluorescence staining, transmission electron microscopy, immunohistochemistry, and ELISA were used to assess ferroptosis. Furthermore, an adeno-associated viral 9 (AAV9) vector encoding SLC7A11 was utilized to validate the protective potential of neuronal SLC7A11 overexpression during diabetic stroke.
resultsDiabetic stroke mice exhibited exacerbated cerebral injury, with differentially expressed proteins notably enriched in ferroptosis. Ferroptosis inhibitors markedly ameliorated neuronal damage in diabetic stroke mice. Additionally, we uncovered inhibited SLC7A11 expression and heightened ferroptosis in the early stages of reperfusion during diabetic stroke. Neuron-specific enforced expression of SLC7A11 mitigated neuronal lipid peroxidation and ferroptosis, providing neuroprotective effects against diabetic cerebral ischemic injury. These protective effects were underscored by the decreased infarct volume, enhanced neurological function, and increased neuronal survival.
conclusionOur study points to SLC7A11 inhibition-mediated ferroptosis as a pivotal factor in the aggravated neuronal damage observed during diabetic stroke. This novel insight opens avenues for potential therapeutic targets in the management of diabetic stroke, focusing on interventions aimed at modulating ferroptosis or SLC7A11 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.